Evaluating the Impact of Adjuvant Use of Beta Blockers on Clinical Outcomes in Patients With Traumatic Brain Injury
Key facts
- Who runs it
- Mansoura University
- Where
- Egypt2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 100 people, planned
- Started
- 20 Jan 2025
- Planned end
- Jun 2025
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- control
- propranolol
- Carvedilol
- Record updated
- 2 April 2025
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Patients with moderate \& severe TBI detected on admission by CT scan and GCS score of ≤ 13 who either do not have any other injuries or only have associated minor injuries; Minor injuries are defined as presence of any of the following:
- Mild intraperitoneal free fluid (IPFF) observed through abdominal ultrasound
- mild lung contusion detected in the chest CT scan
- hemothorax or pneumothorax present without accompanying symptoms of hypoxia, tachypnea, or respiratory distress
- simple limb fractures
Who cannot take part
- Patients on pre-injury beta-blocker therapy
- TBI with GCS ≤ 13 with associated major injuries defined as the presence of any of the following:; Moderate \& marked IPFF requiring surgical intervention ( laparotomy ); moderate \& marked lung contusion, pneumothorax \& hemothorax with accompanying symptoms of hypoxia, tachypnea, lower limbs, or limb amputation; Compound fracture in the upper or lower limb; Open Faciomaxillary trauma
- Patients with any bronchospastic conditions
- Patients with active acute coronary syndrome
- Patients with persistent shock (systemic blood pressure <100 mmHg, base deficit > 4, or oliguria , HR < 60 b/min ) after > one week of admission
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Propranolol primarily acts as a non-selective beta blocker, blocking both beta-1 and beta-2 adrenergic receptors, while carvedilol exhibits a broader spectrum of action by also blocking alpha-1 adrenergic receptors. The receptor blockade profile of a beta blocker can influence its physiological effects and potential therapeutic benefits in TBI. Therefore, the variation in receptor selectivity may result in differences in their impact on secondary brain injury processes and patient outcomes.
The 3 groups in the trial
- Control ArmPlacebo, for comparison
Treatment: control
- propranololExisting treatment, for comparison
- carvedilolExisting treatment, for comparison
Carvid (carvedilol)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Fit questions
- Built from NCT06836856, who can take part
- Record updated
- 2 April 2025